2017 Fiscal Year Final Research Report
Diagnosis and treatment of Langerhans cell histiocytosis by KIR2DL4
| Project/Area Number |
16K19080
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Takei Yusuke
Hirata Masahiro
Sugimoto Akihiko
Kurata Mariyo
Moriyoshi Koki
Haga Hironori
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | KIR2DL4 / ヒトランゲルハンス細胞組織球症 / ERK / SHP-2 |
|---|
| Outline of Final Research Achievements |
We examined the expression and function of KIR2DL4 in LCHs. In pathological specimens, 27 of 36 LCH cases (75.0%) were immunohistochemically positive for KIR2DL4. Its expression was independent of age, gender, location, multi-or single-system, and the status of BRAFV600E immunostaining. We also confirmed the expression of KIR2DL4 mRNA and protein in the human LCH-like cell lines ELD- 1 and PRU-1. KIR2DL4 protein was distributed in the membrane and cytoplasm of ELD-1 cells, but only in the cytoplasm of PRU-1 cells. An agonistic antibody against KIR2DL4 reduced phosphorylation of extracellular signal-regulated kinases (ERKs) and suppressed the cell growth of ELD-1 cells in a Src homology region 2 domain-containing phosphatase-2 dependent manner, but it had no effect in PRU-1 cells. These results suggest that KIR2DL4-mediated ERK suppression is a possible therapeutic target for LCH cells.
|
| Free Research Field |
抑制性受容体
|
